Syneron Medical Ltd

Find Ratings Reports
ELOS : NASDAQ : Health Care
$7.13 | %
Today's Range: 6.97 - 7.18
Avg. Daily Volume: 88,800
07/22/16 - 4:00 PM ET

Financial Analysis


SYNERON MEDICAL LTD's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. SYNERON MEDICAL LTD has strong liquidity. Currently, the Quick Ratio is 1.89 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 8.66% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)68.763.38
EBITDA ($mil)1.711.07
EBIT ($mil)-0.3-1.16
Net Income ($mil)-0.48-1.49


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)68.3183.02
Total Assets ($mil)277.46293.3
Total Debt ($mil)0.00.0
Equity ($mil)204.55223.95


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin54.7655.05
EBITDA Margin2.481.68
Operating Margin-0.43-1.83
Sales Turnover1.020.89
Return on Assets-1.92-1.9
Return on Equity-2.6-2.49
Debt Q1 FY16 Q1 FY15
Current Ratio2.823.1
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)35.2836.75
Div / share0.00.0
EPS-0.01-0.04
Book value / share5.86.09
Institutional Own % n/a n/a
Avg Daily Volume86977.085082.0

Valuation


HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.30 indicates a significant discount versus the S&P 500 average of 2.80 and a significant discount versus the industry average of 4.66. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, SYNERON MEDICAL LTD proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ELOS NM Peers 63.09   ELOS NM Peers 32.41

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ELOS's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ELOS's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ELOS 14.66 Peers 28.28   ELOS NA Peers 1.04

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

ELOS is trading at a valuation on par with its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ELOS 1.30 Peers 4.66   ELOS 0.00 Peers 169.45

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ELOS is trading at a significant discount to its peers.

 

Neutral. Higher earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

The growth rate for ELOS is not available.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ELOS 0.94 Peers 4.72   ELOS 7.95 Peers 19.96

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ELOS is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ELOS significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades